Filing Flows › Fate Therapeutics (FATE) › Q3 2025
Fate Therapeutics (FATE) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Fate Therapeutics (FATE) reported revenue of $1.7M for the third quarter 2025 (Q3 2025), -43% from a year earlier and -9% from the quarter before.
Fate Therapeutics, Q3 2025: revenue $1.7M (-43% year over year), net loss $32.2M, operating cash flow −$24.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | -9% | -43% |
| Operating profit | −$34.7M | — | — |
| Net earnings | −$32.2M | — | — |
| Operating cash flow | −$24.4M | — | — |
What changed
Revenue was $1.7M in Q3 2025, down 43% year over year and down 9% from the previous quarter.
Operating costs exceeded revenue by $34.7M, an operating margin of -1995.1%. Total costs fell 34% while revenue fell 43%. The quarter ended with a net loss of $32.2M, narrower than the previous quarter's $34.1M loss.
Operating cash flow was −$24.4M. Non-cash charges added back $3.2M of depreciation and amortization and $4.9M of share-based compensation. Capital expenditures of $2.2M exceeded it, leaving free cash flow of −$26.6M.
Questions
What was Fate Therapeutics' revenue in the third quarter 2025?
Fate Therapeutics (FATE) reported revenue of $1.7M for the third quarter 2025 (Q3 2025), -43% from a year earlier and -9% from the quarter before.
Source: Fate Therapeutics 10-Q on SEC EDGAR.